united states of america
27 Jan 2026 06:00
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity (globenewswire)
Basel, 27 January 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results...